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Abstract 
Objective: Tobacco smoking significantly impacts clozapine blood levels and has substantial 
implications on individual efficacy and safety outcomes. By investigating differences in clozapine 
blood levels in smoking and non-smoking patients on clozapine, we aim to provide guidance for 
clinicians how to adjust clozapine levels for patients on clozapine who change their smoking 
habits.
Methods: We conducted a meta-analysis on clozapine blood levels, norclozapine levels, 
norclozapine/clozapine ratios and concentration to dose (C/D) ratios in smokers and non-smokers 
on clozapine. Data were meta-analysed using a random-effects model with sensitivity analyses on 
dose, ethnic origin and study quality. 
Results: Data from 23 studies were included in this meta-analysis with 21 investigating 
differences between clozapine blood levels of smokers and non-smokers. In total, data from 7125 
samples were included for the primary outcome (clozapine blood levels in ng/ml) in this meta-
analysis. A meta-analysis of all between-subject studies (N=16) found that clozapine blood levels 
were significantly lower in smokers compared to non-smokers (Standard Mean Difference (SMD) 
-0.39, 95% confidence interval (CI) -0.55 to -0.22, p<0.001, I2=80%). With regard to the 
secondary outcome, C/D ratios (N=16 studies) were significantly lower in the smoker-group 
(n=645) compared to the non-smoker-group (n=813) (SMD -0.70, 95%CI -0.84 to -0.56, 
p<0.00001, I2=17%).
Conclusion: Smoking behavior and any change in smoking behavior is associated with a 
substantial effect on clozapine blood levels. Reductions of clozapine dose of 30% are 
recommended when a patient on clozapine stops smoking. Reductions should be informed by 
clozapine steady-state trough levels and a close clinical risk-benefit evaluation. A
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Summations: 
 Smoking behavior significantly reduces clozapine blood levels 
 When a patient stops smoking, reductions of clozapine dose of 30% are recommended
Considerations: 
 Besides smoking behavior, other factors impacting clozapine blood levels (e.g. age, gender, 
comedication with clinically relevant CYP1A2-interaction, caffeine intake, Cytochrome P-
polymorphisms, ethnic origin) should be accounted for in future studies and, more 
importantly, measurement of clozapine blood levels has to be implemented in future 
studies to provide further evidence for a safe and efficacious use of clozapine
1. Introduction
Clozapine is the most effective antipsychotic agent for treatment-resistant schizophrenia (TRS) (1, 
2).  Clozapine is one of the few antipsychotics where therapeutic level monitoring is used, with 
levels above the maximum threshold (1000 ng/ml) being associated with an increased risk of 
seizures (3). In clinical practice, pseudo-resistance to clozapine may occur as a result of blood 
levels below the minimum threshold definition (350 ng/ml) and there is an association between 
clozapine blood levels and response (4). Cytochrome P450 (CYP) 1A2 (CYP1A2) is the major 
clozapine metabolic enzyme and is responsible for approximately 70% of clozapine’s metabolism 
(5). Clozapine is metabolized to its primary metabolite norclozapine (5). In this regard, polycyclic 
aromatic hydrocarbons generated by tobacco smoking induce the activity of CYP1A2 (6) which 
leads to increased clozapine metabolism. 
Rates of smoking is up to five times higher among people with schizophrenia compared to the 
general population, with smoking rates among people with schizophrenia as high as 60% (7). A 
daily consumption of 7-12 cigarettes  may be sufficient for maximum induction of clozapine 
metabolism (8). Beginning smoking is therefore a clinically relevant risk for relapse and 
inadequate response to clozapine treatment (9) and smoking cessation among clozapine users can 
induce severe clozapine intoxication (10). Ethnicity (Asian heritage) (11, 12), gender (13), age A
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(13-15), CYP-polymorphisms (16), caffeine (17), and comedication with clinically relevant 
CYP1A2-interaction (9) can also influence clozapine blood levels through the CYP-450 system. In 
this context, e.g. people of Asian heritage are presumed to need a lesser clozapine dose compared 
to Caucasian or American populations (12, 18) which might be due to a relatively reduced 
CYP1A2 activity (11). On a similar note, the clinical relevance of CYP1A2 can be observed in 
smoking patients after transition to electronic cigarettes, where the termination of CYP1A2 
induction also induces a clinically relevant increase in clozapine blood levels (19). 
Concentration to dose (C/D) ratio is a measure of clozapine clearance and higher ratios - 
indicating lower clearance - are associated with females, non-smokers, Asians, genetic poor 
metabolizers, CYP-inhibitors, obesity, inflammation and possibly with renal impairment and 
pregnancy (18), whereas lower ratios indicate lack of adherence or are associated with males, 
smokers, non-Asians, and CYP-inducers (18). 
In summary, there is a lack of clarity in the available literature as to how great an influence 
changes in smoking habit can have on clozapine blood levels. To guide clinical care of people 
treated with clozapine, and to assist in averting sub- or supra-therapeutic clozapine levels and their 
associated deleterious effects, we conducted a systematic review and meta-analysis of the impact 
on changes in smoking habit on clozapine blood levels among people on clozapine. Our primary 
outcome of interest was impact on clozapine blood levels, with secondary outcomes of impact on 
clozapine to C/D ratios, norclozapine/clozapine ratios, and norclozapine levels. We planned 
sensitivity analyses and meta-regression analyses on other factors which influence clozapine 
metabolism including ethnicity, age and gender, to assist in clarifying the role of potential 
confounders, if any.
Subtitle: 
To investigate the impact of smoking behavior on clozapine blood levels and clozapine 
concentration to dose ratios in order to provide guidance for clinicians how to manage patients on 
clozapine who smoke or stop smoking. 
Data Availability Statement: A
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The data that support the findings of this study are available from the corresponding author upon 
reasonable request.
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2. Methods
The methods are based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) (20). This study was registered with PROSPERO (registration number 
CRD42020185579), an international database of prospectively registered systematic reviews. 
Searches
Systematic searches were conducted of publications indexed in PubMed, EMBASE and PsycINFO 
using the search terms (level OR levels OR concentration OR concentrations OR ratio OR ratios) 
AND (blood OR serum OR plasma) AND (clozapin* OR clozaril OR zaponex OR denzapin* OR 
clopine OR norclozapine OR desmethylclozapine). The abstracts and titles of articles identified 
through electronic searches were independently screened by two reviewers (EW, LM). 
Publications in all languages were considered for inclusion. 
Inclusion criteria
Studies were included if they reported information on mean (and SD) of clozapine blood levels 
OR C/D ratios for people with psychiatric disorders who were smoking and not smoking in cohort 
studies, case-control studies or randomized or non-randomized controlled trials. 
Exclusion criteria
Case reports and case series were excluded. 
Assessment of reporting strength
As all studies suitable for inclusion were observational studies, we used a modified Newcastle-
Ottawa Quality Assessment Scale (21) for assessment of quality. The maximum score was 5 and 
studies with score of at least 3 were rated as high-quality studies. We considered the following 
domains: representativeness of the sample, sample size, comparability between smokers and non-
smokers, ascertainment of clozapine blood levels (outcome) and quality of descriptive statistics A
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(quality scores are provided in Supplement A Table 2, modified Newcastle-Ottawa Quality 
Assessment Scale is provided in Supplement B). 
Data extraction
Two reviewers (EW, LM) independently extracted the data into an electronic spreadsheet and 
disagreements were resolved by joint examination of the papers. The following data were 
extracted: 
1. Sample size of subjects on clozapine (smokers and non-smokers)
2. Mean (and SD) clozapine blood levels in both groups (ng/ml)
3. Mean (and SD) clozapine dose in both groups (in mg/day)
4. Type of comparison (within-subject or between-subject comparisons between the two 
groups)
The following characteristics of each study were recorded where possible and if available, both 
for male and female participants in both groups separately: 
1. Mean age of subjects in both groups
2. Ratio male:female in both groups
3. Clozapine blood levels and clozapine doses for male and female participants 
4. Whether data collection was prospective or retrospective 
5. Inpatient or outpatient status of subjects
6. Amount of smoking in the smoking group
7. Concentration to dose (C/D) ratio in both groups
8. Norclozapine levels in both groups
9. Norclozapine to clozapine ratios in both groups
Data synthesis and analysis
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
The primary outcome was the clozapine blood level (in ng/ml) in the smoker and non-smoker 
group. Where adequate quantitative data was not reported, corresponding authors were contacted 
to provide means and SDs. Where confidence intervals were reported, these were converted to SD 
using the Cochrane Handbook formula (17). Included studies were divided into between-subject 
studies and within-subject studies. Between-subject studies compared data from subjects on 
clozapine divided into smokers and non-smokers, whereas within-subject studies investigated 
effects within the same individuals as smokers and then non-smokers. Meta-analyses were 
conducted using RevMan (Version 5.3) and meta-regression analyses were conducted using 
Comprehensive Meta-Analysis (Version 3.3). We assessed heterogeneity using the I2 statistic, a 
measure that does not depend on the number of studies in the meta-analysis and hence has greater 
power to detect heterogeneity when the number of studies is small. I2 provides an estimate of the 
percentage of variability due to heterogeneity rather than chance alone. An estimate of 50% or 
greater indicates possible heterogeneity, and scores of 75–100% indicate considerable 
heterogeneity. Given the observational nature of primary studies and expected high rates of 
heterogeneity, a random effects model was used for all the analyses. A significance level of α 
<0.05 was applied for all analyses. 
Subgroup and sensitivity analyses
Subgroup analyses were undertaken for between-subject studies for high-quality (as defined by 3 
out of 5 points on the modified Newcastle Ottawa Scale) vs. low-quality studies, male populations, 
female populations and studies with people from Asian origin vs. studies with people not from 
Asian origin. Meta-regression analyses were performed for between-subject studies for clozapine 
blood levels and the moderators 1) difference in clozapine dose between smokers and non-
smokers 3) proportion of male smokers and 4) proportion of male non-smokers 5) age (smokers) 
and 6) age (non-smokers).
Publication bias
Where meta-analyses included at least 10 studies, publication bias was tested using funnel plot 
asymmetry with Kendall’s Tau, where low p-values suggest publication bias. A threshold of 10 for A
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funnel plots was chosen in accordance with the recommendations from the Cochrane Handbook 
(22). 
3. Results
In total, 7600 articles were independently screened on title/abstract level and 113 articles on full-
text level by two reviewers. A total of 90 articles were excluded at full text review (see 
Supplement A Table 1 for list of excluded studies with reasons), with 23 articles (8, 16, 23-43) 
included in the meta-analysis (see Fig. 1, List of included studies see Table 1). Twenty-one articles 
(8, 16, 23-31, 34-43) investigated differences between smokers and non-smokers as between-
subject analyses and two studies (32, 33) compared differences as within-subject analyses change 
of blood levels among smokers after institutional smoking ban). In total, data from 7125 samples 
were included for the primary outcome (clozapine blood levels in ng/ml) in this meta-analysis. Of 
these, 4925 were from smokers and 2185 from non-smokers (N=21, between-subject analyses) 
and 15 were smokers and subsequent non-smokers (N=2, within-subject analyses). 18 out of 23 
studies were performed exclusively in schizophrenia-spectrum populations, with the remaining 
five additionally including (a small amount of) patients with bipolar disorder (26, 33), unspecified 
psychiatric disorders (38, 43) and psychiatric disorders except organic disorders (27). 
Between-subject analyses
a) Clozapine blood levels 
16 studies (8, 23, 25-31, 34, 35, 37-39, 41, 42) reported on blood levels for samples of smokers 
(n=4925) and non-smokers (n=2185). Overall, study quality was moderate, with 6/16 rated as 
high-quality (23, 26, 31, 35, 39, 41) and 10 as low/moderate-quality according to modified 
Newcastle-Ottawa Rating Scale (see Supplementary File B). Four studies were retrospective (23, 
26, 27, 41) and 12 prospective (8, 25, 28-31, 34, 37-39, 42). All except three studies (26, 27, 38) 
were exclusively covering people with schizophrenia-spectrum disorders. From these 16 studies, 
four (28-30, 41) were restricted to people of Asian origin. 
A meta-analysis of all between-subject studies (N=16) found that clozapine blood levels were 
statistically significantly lower by more than a third in smokers compared to non-smokers A
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(Standard Mean Difference (SMD) -0.39, 95% confidence interval (CI) -0.55 to -0.22, p<0.00001,  
I2=80%) (see Figure 2). On sensitivity analyses, when restricted to the six high-quality studies 
(n=4393 samples in the smoker-group and n=1583 samples in the non-smoker group), results 
remained significant (SMD -0.29, 95%CI -0.51 to -0.07, p<0.009) (see Supplement A Figure 1). 
Neither the difference between clozapine dose for smokers or non-smokers (Q=0.04, df=1, p=0. 
848) nor age of smokers or non-smokers significantly impacted the effect size in a meta-regression 
(Q=0.36, df=2, p=0.834).
Nevertheless, a higher proportion of male participants among smokers and non-smokers had 
increased the effect size (Q=18, df=2, p=0.0001). Scatterplots for moderator variables are 
displayed in the Supplement A Fig. 19-25. There was no evidence of publication bias (τ=-0.05, 
p=0.77, see Supplement A Table 3). 
When restricted to the five studies conducted among people with Asian origin, results were not 
significant (SMD -0.43, 95% CI -0.97 to 0.11, p=0.12). However, there was one outlier study (41) 
from Asia where levels in the smoker-group were reported to be higher than in the non-smoker 
group (see Supplement A Fig. 2). When this study was removed (N=4 studies, 75 smokers vs. 127 
non-smokers), results were significant (SMD -0.63, 95%CI -1.05 to -0.21, p=0.003). When the 
analysis was restricted to non-Asian studies, results were also significant (SMD -0.39, 95%CI -
0.58 to -0.21, p<0.0001) (see Supplement A Fig. 3). 
There was insufficient relevant data to conduct sensitivity analysis or meta-regression for gender.  
b) clozapine dose
Sixteen studies reported on associated clozapine doses (in mg per day) for samples of smokers 
(n=4925) and non-smokers (n=2185). Doses were significantly higher in the smoker-group 
compared to the non-smoker group (SMD 0.22, 95%CI 0.07 to 0.36, p<0.003) with high between-
sample heterogeneity (p<0.00001, I2=71%) (see Supplement A Fig. 4). When analyses were 
restricted to the six high-quality studies, results were not significant (SMD 0.14, 95%CI -0.03 to 
0.31, p=0. 11) between samples of smokers (n=4393) and non-smokers (n=1583) (see Supplement 
A Fig. 5). When restricted to studies among people with Asian origin (N=4), doses were 
significantly higher in smokers (n=125) compared to non-smokers (n=218) (SMD 0.33, 95%CI 
0.01 to 0.65, p=0.04) (see Supplement A Fig. 6). When restricted to non-Asian studies, results A
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were similar for associated doses between samples of smokers (n=4800) and non-smokers 
(n=1967) (SMD 0.18, 95%CI 0.03 to 0.33, p=0.02) (see Supplement A Fig. 7). There was not 
enough data for additional analyses (e.g. male vs. female comparisons). 
c) norclozapine/clozapine ratio
Five studies (23, 24, 28, 30, 35) reported on norclozapine/clozapine ratios for samples of smokers 
(n=4232) and non-smokers (n=1460), with no significant difference in norclozapine/clozapine 
ratios between the two groups (SMD -0.00, 95%CI -2.04 to 2.03, p=1.00) (see Supplement A Fig. 
8). There was not enough data for additional analyses. 
d) norclozapine blood levels 
Seven studies (23, 28-30, 34, 35, 38) reported on norclozapine blood levels for samples of 
smokers (n=4321) and non-smokers (n=1643). There was no significant difference between the 
two groups (SMD -0.08, 95%CI -0.19 to 0.04, p=0.18) with low/moderate heterogeneity (p=0.12, 
I2=39%) (see Supplement A Fig. 9). When restricted to five non-Asian studies, results remained 
non-significant between samples of smokers (n=4263) and non-smokers (n=1512) (SMD -0.05, 
95%CI -0.16 to 0.07, p=0.44) (see Supplement A Fig. 10). There was not enough data for 
additional analyses. 
e) C/D ratio 
Eight studies (8, 16, 23, 24, 27, 36, 40, 43) reported on C/D ratios for smokers (n=645) and non-
smokers (n=813). C/D ratios were statistically significantly lower in the smoker-group  (SMD -
0.70, 95%CI -0.84 to -0.56, p<0.00001) with low between-sample heterogeneity (p=0.28, I2=17%) 
(see Supplement A Fig. 11). In a sensitivity analysis restricted to four high-quality samples, results 
remained significant between smokers (n=140) and non-smokers (n=349) (SMD -0.58, 95%CI -
0.83 to -0.34, p<0.00001) (see Supplement A Fig. 12). In a sensitivity analysis restricted to five 
samples of people from Asian origin from one study (36) with n=138 smokers and n=432 non-
smokers, results remained significant (SMD -0.59, 95%CI -0.79 to -0.39, p<0.00001) with low 
between-sample heterogeneity (p=0.39, I2=2%) (see Supplement A Fig. 13). When restricted to A
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seven non-Asian studies, results remained significant between smokers (n=507) and non-smokers 
(n=381) (SMD -0.78, 95%CI -0.97 to -0.59, p<0.00001) (see Supplement A Fig. 14). There was 
not enough data for additional analyses (e.g. male vs. female comparisons). 
Within-subject analyses
Clozapine blood levels
A meta-analysis of two within-subject studies (32, 33) found significantly increased levels after 
transition from smoking status (n=15) to non-smoking status (n=15) (SMD -0.84, 95%CI -1.60 to -
0.08, p=0.03) (see Supplement A Fig. 15). There was insufficient data for further analyses. 
4. Discussion
This meta-analysis from a total of N=23 studies comprising more than 7000 subjects with 
psychiatric disorders represents the most comprehensive analysis on the relationship of clozapine 
levels/ratios and smoking to date. We found that clozapine blood levels are reduced by around a 
third in smokers compared to non-smokers. Our analysis is the first to comprehensively combine 
and quantify published data on the impact of smoking on clozapine levels. For patients on 
clozapine who smoke and subsequently quit smoking, dosages should be decreased by 30% and 
clozapine blood level analyses should be performed. It is important to note that the CYP1A2 
activity decrease may be a gradual process over the first three to four days after smoking cessation 
(44). Conversely, if patients start to smoke clozapine blood levels may fall by 30% resulting in the 
need to increase the dose and to monitor blood levels. In this regard clinical signs of clozapine 
underdosing, such as anxiety, restlessness and sleep disturbances must be monitored in patients 
who commence smoking. 
In our analyses clozapine blood levels were significantly lower in smokers. However, there may 
be unaccounted for confounding factors. Co-occurring caffeine intake might have increased 
clozapine blood levels due to CYP1A2 inhibition as previously observed in the literature (17). 
Smoking and caffeine use may co-occur among people with schizophrenia (45). Thus, differences 
in blood levels between smokers and non-smokers might have been underestimated since none of 
the included studies controlled for caffeine consumption. We were not able to conduct sensitivity A
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analyses for caffeine as this data was not reported. We were only able to include information on 
other reported relevant CYP-450 interacting comedication. 
C/D ratios were significantly lower in smokers in our analyses and our results remained significant 
when analyses were restricted to high-quality studies or studies from Asian origin. This allows for 
adjustment for certain factors associated with CYP activity such as Asian genetic heritage. 
However, impact of other factors associated with influence on C/D ratios (e.g. gender, poor 
metabolizer, obesity, inflammation) were not able to be controlled for in our analyses. 
Furthermore, we were able to undertake meta-regressions examining the impact of dose, age and 
gender on clozapine blood levels between smokers and non-smokers. Our findings regarding the 
influence of gender on clozapine blood levels with smoking should be treated with caution, since 
only three studies reported blood levels (33, 35, 39), one reported C/D ratios (36) between 
smokers and non-smokers for male and female populations separately and one study only included 
only one gender (41). In one of the studies which disaggregated data by gender and smoking 
status, only 14% of men were non-smokers (35), which may have skewed the results. Between-
subject analyses may be biased since the included studies, with the exception of Lu et al. (30), 
were not fixed-dose studies and doses in smokers might have been increased by the treating 
clinicians. Thus, the true difference induced by smoking might be bigger than estimated, as 
suggested by within-subject analyses based on limited subject numbers. Furthermore, one study 
from Rostami et al. reported samples of smokers and non-smokers, and thus various samples 
might be derived from the same patients increasing the risk of bias.  
Our analyses had a high degree of heterogeneity, and as such our results should be viewed with 
caution. We were able to conduct sensitivity analyses and meta-regression on dose, gender, 
ethnicity and age. There was insufficient data to permit meta-regression for comedications, 
smoking quantity, genetics for fast metabolizer, caffeine use or body weight, since none of the 
included studies reported these confounders for smokers and non-smokers homogenously allowing 
for meta-analyses. Nevertheless, comedication was considered as an item in our Assessment of 
reporting strength and thus high-quality studies excluded clinically relevant CYP1A2 interacting 
comedication. Furthermore, seven out of our included studies were retrospective analyses which 
may be more prone to bias than prospective approaches, especially since data may not be available 
on medication adherence and ascertainment of smoking behavior is less certain. We attempted to 
address this through our sensitivity analysis of study quality. A
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Ours is the largest meta-analysis on clozapine blood levels and C/D ratios from a total of four 
studies (46). In contrast to the work from Tsuda et al., we included studies of patients of Asian 
heritage, assessed risk of bias and conducted sensitivity analyses and meta-regression analyses, if 
possible. Based on their meta-analysis on C/D ratios, Tsuda et al. estimated that if 200 and 400mg 
per day of clozapine would be administered to smokers, about 100 and 200mg per day, 
respectively, should be administered to non-smokers, based on a SMD C/D ratio of 1.1 (46). In our 
analyses, SMD of C/D ratio between smokers and non-smokers (0.7 ng/ml per mg/day) was lower 
than in the one from Tsuda et al. suggesting an estimated 30% reduction of dose after a patient 
stops smoking. 
Conclusion
Our meta-analysis confirms that smoking behavior and any change in smoking behavior is 
associated with substantial clinical implications for patients on clozapine and extends the current 
knowledge by providing an evidence-based quantification of these effects. According to our 
analyses, reductions of clozapine dose by 30% are recommended when a patient on clozapine 
stops smoking. Nevertheless, reductions have to be performed with TDM of clozapine steady-state 
trough levels and a clinical risk-benefit evaluation since high variability between individuals (95% 
CI in the range of -0.55 to -0.22 in our analyses) has to be expected. Dose reductions should be 
combined with instruction of patient and nurses (for signs of intoxication and relapse) and a close 
monitoring of clozapine blood levels.
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Tables and Figures: 
Table 1: Description of included studies 
Values of age, clozapine dose and clozapine blood levels were rounded to whole numbers. 
In the publication from Rostami et al., TDM sample cases were reported instead of number of 
patients. 
Legend: 
*mean cigarettes per day (and SD) in smoking group
**except organic mental disorders
*** during the treatment period (46.2±25.4 months), the medication dose was adjusted by 
physicians based on therapeutic response and adverse effects (…) When the clozapine dose was A
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changed, the steady-state serum concentration was measured after at least 7 days of constant 
dosing“ (Lee, 2009). 
#: From n=14, those excluded where dose pre-post not stable or who were caught smoking after 
the ban (n=10), age mean =39.75 yrs, SD=9.11, 3 men, 1 woman. 
##: multiple samples/patient
###: SD calculated from 95%CIs: smokers 38.8 years 95%CI (19.0-72.0), non-smokers 44.32 
years 95%CI (19-88).
#### levels in week 8 were taken for analyses. 
Abbrev.: BD=bipolar disorder, cigs=cigarettes, d=day, DSM-IV=Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition, DSM-III= Diagnostic and Statistical Manual of Mental 
Disorders, 3rd Edition, DSM-III-R= Diagnostic and Statistical Manual of Mental Disorders, 3rd 
Edition, Text Revision, f=female, ICD-10=International Classification of Diseases, 10th Revision, 
m=male, m:f=male to female ratio, mg/d=milligram per day, n=no, ns=not specified, SD=standard 
deviation, Sz=schizophrenia, TDM=therapeutic drug monitoring, TR-Sz=treatment-resistant 
schizophrenia, y=yes, yrs=years. 
Figure 1: PRISMA-Flowchart (study selection process)
Systematic literature search according to Moher D et al., 2009. 
Figure 2: Clozapine blood levels (ng/ml) in between-subject comparisons of smokers vs. non-
smokers
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